Compare Norfolk Southern Corporation (NSC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs 10X Genomics Inc — how do they compare? Norfolk Southern Corporation trades at $316.88 (market cap $71.20B), while 10X Genomics Inc trades at $84.15 (market cap $10.07B). The key difference: Norfolk Southern Corporation is far larger — about 7.1× 10X Genomics Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and 10X Genomics Inc for 92 Days on average.
| NSC | TXG | |
|---|---|---|
Market Cap | $71.20B | $10.07B |
Volume | 555,248 | 5,657,286 |
Sector | Industrials | Health |
52-Week High | $352.98 | $97.74 |
52-Week Low | $278.19 | $11.48 |
Typical Hold Time | 33 Days | 92 Days |
Enterprise Value | $86.75B | $9.59B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $313.20, down 0.98% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.52 exceeding the $3.32 forecast. Key developments include the proposed merger with Union Pacific, which is progressing through regulatory review and expected to close by late 2027. Financial metrics show solid profitability with 21.02% net income margin and 16.97% ROE, though cash flow trends indicate negative net cash flow in both 2025 and 2026.
The investment case balances strong operational performance against merger execution risks and technical weakness. With 44% analyst buy ratings and a $361.86 consensus price target suggesting 15% upside, the stock offers value if merger benefits materialize. However, regulatory hurdles, fuel cost pressures, and bearish technical signals warrant caution for near-term investors.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
